You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.
The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.
IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.
The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.
A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.
In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.